Artiva Biotherapeutics Inc., of San Diego, has secured $78 million in series A financing to support its development of off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor-targeting CAR-NK cell therapies.
LONDON – Enterome SA has raised €46.3 million (US$52.6 million) in a mixture of debt and equity, enabling it to take a new type of cancer vaccine, based on microbiome-derived antigens that mimic neoantigens expressed on tumor cells, into the clinic.
Nearly a week after filing for a $115 million IPO that it had put off for more than a year, and two months after dosing the first patient in its phase I trial in metastatic castration-resistant prostate cancer, Poseida Therapeutics Inc. has closed on a $110 million series D to continue its CAR T-cell therapy programs.
Startup Brightinsight Inc. is working to make the infrastructure behind digital health easily accessible to pharma and med-tech companies. To aid it on this path, the San Jose, Calif.-based company has raised a $40 million series B round to expand its capabilities and global reach.
Okami Medical Inc., which last year gained the U.S. FDA’s nod for the LOBO vascular occlusion system, has reported the close of a series D financing totaling $7.2 million. The round was led by U.S. Venture Partners and joined by members of Okami's board and other stakeholders.
Startup Foldax Inc. has raised a $20 million series D round to back its development of biopolymer-based surgical and minimally invasive heart valves. Heart valves typically are either based on porcine or bovine tissues or are mechanical.
RSS
